We synthesized 46 sequential peptides 21 to 39 amino acids long over the structural protein of human T-cell leukemia virus type I (HTLV-I; the p19 and p24 gag protein and the gp46 and p2OE env proteins) and tested their reactivities against antibodies in sera from HTLV-I healthy carriers and patients diagnosed as having human T-cell leukemia-lymphoma (ATLL) and myelopathy (HAM) by using an enzyme-linked immunosorbent assay. Of the 46 synthetic peptides, 18 peptides (2 corresponding to the p19 gag protein, 2 corresponding to the p24 gag protein, 8 corresponding to the gp46 env protein, and 6 corresponding to the p2OE env protein) reacted with antibodies in the sera from HTLV-I healthy carriers. In particular, the peptides comprising amino acids 100 to 119 and 119 to 130 of the gag and 175 to 199, 213 to 236, 253 to 282, and 288 to 317 of the env proteins reacted with antibodies in sera from more than 30% of HTLV-I healthy carriers. These peptides also showed high reactivities to the antibodies in the sera from patients with ATLL and HAM. The results indicate that the predominant antigenic regions of the structural protein of HTLV-I were located at the C-terminal end of the p19 gag protein and the C-terminal half of the gp46 env protein, and the corresponding peptides proved to be useful antigens in detecting antibodies in the sera from individuals infected with HTLV-I.
Human T-cell leukemia virus type I (HTLV-I) is closely associated with adult T-cell leukemia-lymphoma (ATLL) (3, 5, 10, 14) and human adult myelopathy (HAM)-tropical spastic paraparesis (4, 9) . This virus is known to be transmitted from mother to infant by breast feeding (2) , from husband to wife by sexual intercourse (13) , and by blood transmission (8) . In these transmissions, the HTLV-I infection is confirmed by the detection of antibodies to several gene (gag, pol, env, and X) products of HTLV-I. Sato et al. (11) reported that in recipients that were seroconverted by blood transfusion, immunoglobulin M (IgM) antibody against gp46 was first detected about 2 weeks after receiving blood, IgM and IgG antibodies to p19 and p24 were found in weeks 4 to 6, and then IgG antibody to gp46 was found about 9 weeks after transfusion. These results suggest that individuals infected with HTLV-I may show various antibody profiles to HTLV-I associated with the transmission routes and the amount of the virus acquired at the time of exposure. Accordingly, it is important to analyze the antibody profile of individuals infected with HTLV-I so that the most useful antigenic region of HTLV-I for diagnosis of HTLV-I infection can be identified.
We have previously shown that the synthetic peptides derived from the putative amino acid sequence of HTLV-I is a useful antigen in the detection of antibodies against HTLV-I (6). Therefore, using the sequential synthetic peptides which cover the structural proteins of HTLV serum and 0.05% Tween 20 were added to the coated microtiter wells and incubated at 37°C for 1 h after six washes with PBS containing 0.05% Tween 20. The plate were further incubated with goat antibodies to human IgG conjugated with horseradish peroxidase (MBL Ltd., Nagoya, Japan) at 37°C for 30 min. The plates were washed six times and developed with 150 ,ul of 0.1% H202 and 0.04% ortho-phenylenediamine in 0.1 M sodium citrate buffer (pH 5.5). The reaction was stopped by the addition of 50 RI of 2.5 M H2SO4, and the color development was measured in a plate reader (SLT Labinstrument, Salzburg, Austria) at 492 nm. The cutoff level used to determine seropositivity was calculated by statistical analysis as the mean value of 31 serum samples which were PA negative and IF negative plus 3 standard deviations. In a competitive ELISA for confirmation, serum specimens preincubated with 5 jig of synthetic peptides or PBS at 37°C for 30 min were added to microtiter wells coated with the peptide. A serum sample showing more than a 30% decrease of absorbance in the competitive ELISA was judged to be positive.
RESULTS
To determine the antigenic regions of the structural proteins of HTLV-I, we synthesized (with an automated peptide synthesizer) 46 sequential peptides 11 to 39 amino acids long, overlapping by 1 to 5 amino acids, over the p19 and p24 gag proteins and the gp46 and p2OE env proteins. By using the ELISAs with 96 wells of microtiter plates coated with the peptides as antigens, we were able to test the peptides reactivities against antibodies in the sera from 96 HTLV-I healthy carriers. Figure 1 shows the percentage of incidence of the positive serum samples for the antibody response of the individual peptide. Of the 46 synthetic peptides tested, 18 (2 derived from the p19 gag protein, 2 derived from the p24 gag protein, 8 derived from the gp46 env protein, and 6 derived from the p2OE env protein) reacted with antibodies in the sera from HTLV-I healthy carriers. In the group of the p19 gag protein, the peptides from amino acids 100 to 119 and 119 to 130, which corresponded to the C-terminal of the p19 gag protein, reacted with antibodies in 84 (85%) and 38 (39%), respectively, of the 96 serum samples. As described in a previous paper, the peptide comprising amino acids 100 to 130 corresponding to the C-terminal end 30 amino acids of the p19 gag protein reacted with antibodies in all serum samples from HTLV-I healthy carriers (6 (1) reported that the recombinant p19 and p24 gag protein and the C-terminal region (amino acids 229 to 308) of the gp46 env protein were able to detect the antibodies in all eight serum samples from individuals found to be positive by particle agglutination assay, immunofluorescence assay and Western immunoblot analysis. The sensitive detection of the antibodies by using recombinant p19 gag and the C-terminal region of the gp46 env protein reported by them are in close agreement with data presented here. However, in the present study we failed to define the highly reactive peptides derived from the p24 gag protein for antibody binding. Although the discrepancy in reactivities for antibody binding by the synthetic peptides and the recombinant p24 gag protein could not be clarified, there are some possible explanations: (i) the synthetic peptide selected for use in this experiment did not cover an immunodominant epitope, (ii) the majority of antigenic determinants on the p24 gag protein may be conformational rather than sequential, and (iii) the antigen produced from infected tissue culture cells or by genetic engineering techniques with expression vectors inevitably contained some nonviral proteins that could have caused a false-positive assay in the results.
